Serotype Distribution and Antimicrobial Resistance of Invasive S. pneumoniae among Indian Children before the Introduction of Pneumococcal Conjugate Vaccine

Abstract

This study was conducted to provide current information on serotype distribution and drug resistance patterns of invasive Streptococcus pneumoniae among children. Sterile site samples from 1,504 children ≤5 years, who were clinically and radiologically suspected of having invasive pneumococcal infection were evaluated. The leading serotypes causing invasive pneumococcal disease (IPD) were 1, 6B, and 14. High-level penicillin resistance was observed in 11% of isolates belonging to serotypes 6B, 1, and 5. Multidrug resistance was observed in 24% of strains. Our results reveal that PCV-10 and PCV-13 vaccines can protect against 68% and 78% of IPD serotypes, respectively.

Keywords

invasive pneumococcal disease - serotyping - antimicrobial resistance

• References

• 1 Tan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev 2012; 25 (3) 409-419
• 2 Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children: use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). Atlanta, GA: Dept. of Health and Human Services, Centers for Disease Control and Prevention; 2010
• 3 Jaiswal N, Singh M, Thumburu KK , et al. Burden of invasive pneumococcal disease in children aged 1 month to 12 years living in South Asia: a systematic review. PLoS One 2014; 9 (5) e96282
• 4 Huang S, Liu X, Lao W , et al. Serotype distribution and antibiotic resistance of Streptococcus pneumoniae isolates collected at a Chinese hospital from 2011 to 2013. BMC Infect Dis 2015; 15: 312
• 5 Hackel M, Lascols C, Bouchillon S, Hilton B, Morgenstern D, Purdy J. Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations. Vaccine 2013; 31 (42) 4881-4887
• 6 Joloba ML, Bajaksouzian S, Palavecino E, Whalen C, Jacobs MR. High prevalence of carriage of antibiotic-resistant Streptococcus pneumoniae in children in Kampala Uganda. Int J Antimicrob Agents 2001; 17 (5) 395-400
• 7 Adetifa IM, Antonio M, Okoromah CA , et al. Pre-vaccination nasopharyngeal pneumococcal carriage in a Nigerian population: epidemiology and population biology. PLoS One 2012; 7 (1) e30548
• 8 Martín-Galiano AJ, de la Campa AG. High-efficiency generation of antibiotic-resistant strains of Streptococcus pneumoniae by PCR and transformation. Antimicrob Agents Chemother 2003; 47 (4) 1257-1261
• 9 Stephanie JS, Bernard B, Scott D . Resistant pneumococcal infections: the burden of disease and challenges in monitoring and controlling antimicrobial resistance, WHO/CDS/CSR/DRS/2001.6
• 10 Tleyjeh IM, Tlaygeh HM, Hejal R, Montori VM, Baddour LM. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2006; 42 (6) 788-797
• 11 Van Bambeke F, Reinert RR, Appelbaum PC, Tulkens PM, Peetermans WE. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs 2007; 67 (16) 2355-2382
• 12 Guevara M, Barricarte A, Torroba L , et al; Working Group for Surveillance of the Pneumococcal Invasive Disease in Navarra. Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case-control study. Euro Surveill 2016; 21 (14)
• 13 Whitney CG, Farley MM, Hadler J , et al; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348 (18) 1737-1746
• 14 Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998–2003. MMWR Morb Mortal Wkly Rep 2005; 54 (36) 893-897
• 15 Moore MR, Gertz Jr RE, Woodbury RL , et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008; 197 (7) 1016-1027
• 16 Institute of Environmental Science and Research Ltd. New Zealand. Invasive Pneumococcal Disease Reports [Internet]. Wellington (NZ): Population and Environmental Health Institute of Environmental Science & Research Limited Kenepuru Science Centre. [cited 2014 Jan 30]. Available from: http://www.surv.esr.cri.nz/surveillance/IPD.php
• 17 Kaplan SL, Barson WJ, Lin PL , et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32 (3) 203-207
• 18 Statens Serum Institut (SSI). Invasive pneumococcal disease and PCV coverage 2012. EPI-NEWS, No 19, 2013 . Copenhagen: SSI; 8 May 2013. Availablefrom: http://www.ssi.dk/English/News/EPI-NEWS/2013/No%2019%20%202013.aspx
• 19 World Health Organization. Pneumococcal conjugate vaccine for childhood immunization – WHO position paper. Wkly Epidemiol Rec 2007; 82 (12) 93-104
• 20 Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5.  year after conjugate vaccine introduction-eight states, 1998–2005. MMWR Morb Mortal Wkly Rep 2008; 57 (6) 144-148
• 21 Facklam RR, Washington JA. Manual of Clinical Microbiology. In: Balows A, Hauser WJ, Herman KL, lsenberg HD, Shadomy HJ, , ed. 5th ed. Streptococci and related catalase negative gram positive cocci. Washington DC: American Society for Microbiology; 1991: 238-257
• 22 Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. ; 25th informational supplement, M100-S23 , Wayne, Pa:CLSI. 2015. ; 33
• 23 Publication WHO ; WHO Publication. Pneumococcal vaccines WHO position paper – 2012–recommendations. Vaccine 2012; 30 (32) 4717-4718
• 24 Johnson HL, Deloria-Knoll M, Levine OS , et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010; 7 (10) e1000348
• 25 Choi EH, Kim SH, Eun BW , et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 2008; 14 (2) 275-281
• 26 Rückinger S, von Kries R, Reinert RR, van der Linden M, Siedler A. Childhood invasive pneumococcal disease in Germany between 1997 and 2003: variability in incidence and serotype distribution in absence of general pneumococcal conjugate vaccination. Vaccine 2008; 26 (32) 3984-3986
• 27 Manoharan A . ASIP Study group 2013. Surveillance of Invasive Disease caused by Streptococcus pneumoniae or Haemophilus influenzae or Neisseria meningitidis in Children (<5 years) in India. Poster presentation. Milan: European Society for Paediatric Infectious Diseases;
• 28 Nisarga R, Premalatha R Shivananda, et al. Hospital-based surveillance of invasive pneumococcal disease and pneumonia in South Bangalore, India. Indian Pediatr 2015; 52 (3) 205-211
• 29 Prospective multicentre hospital surveillance of Streptococcus pneumoniae disease in India. Invasive Bacterial Infection Surveillance (IBIS) Group, International Clinical Epidemiology Network (INCLEN). Lancet 1999; 353 (9160) 1216-1221
• 30 Kanungo R, Rajalakshmi B. Serotype distribution & antimicrobial resistance in Streptococcus pneumoniae causing invasive & other infections in south India. Indian J Med Res 2001; 114: 127-132
• 31 Saha SK, Rikitomi N, Biswas D , et al. Serotypes of Streptococcus pneumoniae causing invasive childhood infections in Bangladesh, 1992 to 1995. J Clin Microbiol 1997; 35 (3) 785-787
• 32 Rijal B, Tandukar S, Adhikari R , et al. Antimicrobial susceptibility pattern and serotyping of Streptococcus pneumoniae isolated from Kanti Children Hospital in Nepal. Kathmandu Univ Med J (KUMJ) 2010; 8 (30) 164-168
• 33 Kumar K L R, Ganaie F, Ashok V. Circulating Serotypes and Trends in Antibiotic Resistance of Invasive Streptococcus Pneumoniae from Children under Five in Bangalore. J Clin Diagn Res 2013; 7 (12) 2716-2720
• 34 Scott JA, Hall AJ, Dagan R , et al. Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease. Clin Infect Dis 1996; 22 (6) 973-981
• 35 Liu C, Xiong X, Xu W, Sun J, Wang L, Li J. Serotypes and patterns of antibiotic resistance in strains causing invasive pneumococcal disease in children less than 5 years of age. PLoS One 2013; 8 (1) e54254
• 36 Goyal R, Singh NP, Kaur M, Talwar V. Antimicrobial resistance in invasive and colonising Streptococcus pneumoniae in North India. Indian J Med Microbiol 2007; 25 (3) 256-259
• 37 Song JH, Jung SI, Ko KS , et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004; 48 (6) 2101-2107
• 38 Klugman KP, Koornhof HJ. Drug resistance patterns and serogroups or serotypes of pneumococcal isolates from cerebrospinal fluid or blood, 1979–1986. J Infect Dis 1988; 158 (5) 956-964
• 39 Balaji V, Jayaraman R, Verghese VP, Baliga PR, Kurien T. Pneumococcal serotypes associated with invasive disease in under five children in India & implications for vaccine policy. Indian J Med Res 2015; 142 (3) 286-292
• 40 Arifeen SE, Saha SK, Rahman S , et al. Invasive pneumococcal disease among children in rural Bangladesh: results from a population-based surveillance. Clin Infect Dis 2009; 48 (Suppl. 02) S103-S113
• 41 Batuwanthudawe R, Karunarathne K, Dassanayake M , et al. Surveillance of invasive pneumococcal disease in Colombo, Sri Lanka. Clin Infect Dis 2009; 48 (Suppl. 02) S136-S140
• 42 Chawla K, Gurung B, Mukhopadhyay C, Bairy I. Reporting Emerging Resistance of Streptococcus pneumoniae from India. J Glob Infect Dis 2010; 2 (1) 10-14
• 43 Park IH, Moore MR, Treanor JJ , et al; Active Bacterial Core Surveillance Team. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 2008; 198 (12) 1818-1822
• 44 Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 2011; 29 (41) 7207-7211
• 45 Su WJ, Lo HY, Chang CH , et al. Effectiveness of Pneumococcal Conjugate Vaccines of Different Valences Against Invasive Pneumococcal Disease Among Children in Taiwan: A Nationwide Study. Pediatr Infect Dis J 2016; 35 (4) e124-e133
• 46 Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?. BMC Pediatr 2010; 10: 4
• 47 Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 2010; 28 (26) 4249-4259
• 48 Lalitha MK, Pai R, Manoharan A, Appelbaum PC ; CMCH Pneumococcal Study Group. Multidrug-resistant Streptococcus pneumoniae from India. Lancet 2002; 359 (9304) 445
• 49 Bokaeian M, Khazaei HA, Javadimehr M. Nasopharyngeal Carriage, Antibiotic Resistance and Serotype Distribution of Streptococcus Pneumoniae among Healthy Adolescents in Zahedan. Iran Red Crescent Med J. 2011; 13 (5) 328-333